FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Sci / Safety Assessment of an Oral Therapeutic Dose of Firocoxib o...
Veterinary sciences2023; 10(9); doi: 10.3390/vetsci10090531

Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses.

Abstract: Firocoxib is a non-steroidal anti-inflammatory drug specifically formulated for veterinary medicine and selectively acts on inhibiting the cyclooxygenase 2 enzyme (COX-2). This study evaluated the possible adverse effects of administering oral therapeutic firocoxib on gastric mucosa, hematological parameters, coagulation cascade, and hepatic and renal biochemistry in healthy horses. Nine clinically healthy Arabian horses, approximately 9 years old, received 0.1 mg/kg of oral firocoxib for 14 days. The gastroscopic examination was conducted 1 day before starting treatment (D0) and two days after the last blood collection (D23). Venous blood samples were obtained for laboratory tests on day 1, immediately prior to the initiation of treatment (D1), after 7 and 14 days of treatment (D7 and D14), and 7 days after the conclusion of treatment (D21. No changes were found in the gastroscopic and hematological tests. Coagulation and serum biochemistry levels remain between these species' average values. However, the increased activated partial thromboplastin time (aPTT) and prothrombin time (PT) indicate reduced blood coagulation capacity, which contradicts the expected effect of treatment with selective COX-2 inhibitors, as these drugs theoretically promote coagulation. Administering firocoxib to horses is safe as it does not cause significant adverse reactions. Therefore, it is a suitable option for managing inflammatory conditions in these animals with attention to an unexpected adverse anti-coagulopathy effect, and further study is warranted.
Get Full Text
Publication Date: 2023-08-22 PubMed ID: 37756053PubMed Central: PMC10535825DOI: 10.3390/vetsci10090531Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explored the impact of administering an oral therapeutic dose of an anti-inflammatory drug, Firocoxib, to healthy horses. The study’s results showed no significant adverse reactions, proposing that Firocoxib can be used to manage inflammatory conditions in horses.

Study Design and Methodology

  • The research was conducted on nine clinically healthy Arabian horses, approximately nine years old.
  • Each horse received a dose of 0.1 mg/kg of oral Firocoxib for 14 days.
  • Assessments were made before administration (D0), after 7 and 14 days of treatment (D7 and D14), and 7 days post-treatment (D21).
  • Tests conducted included a gastroscopic examination, hematological tests, and coagulation and serum biochemistry tests.
  • Gastroscopic examination was performed before starting treatment (D0) and two days after the last blood collection (D23).

Firocoxib and Its Implication

  • Firocoxib is a non-steroidal anti-inflammatory drug designed specifically for veterinary medicine.
  • It works by selectively inhibiting the cyclooxygenase 2 enzyme (COX-2) which is involved in inflammation and pain pathways in animals.

Key Findings

  • The gastroscopic and hematological results showed no changes, indicating that the drug caused no harmful effects on the gastric mucosa and blood cells.
  • Coagulation and serum biochemistry levels remained within the average values of these species.
  • However, the study noted an increased activated partial thromboplastin time (aPTT) and prothrombin time (PT), indicating a reduced ability of the blood to coagulate.
  • This finding is surprising as selective COX-2 inhibitors are expected to facilitate coagulation, not reduce it.

Conclusion

  • The research concludes that administration of Firocoxib in horses appears safe as it doesn’t provoke significant adverse reactions.
  • Consequently, Firocoxib is a suitable choice for the management of inflammatory conditions in horses.
  • However, its unexpected anti-coagulopathy effect warrants further exploration.

Cite This Article

APA
Araújo RA, Sales NAA, Basile RC, Feringer-Junior WH, Apparício M, Ferraz GC, Queiroz-Neto A. (2023). Safety Assessment of an Oral Therapeutic Dose of Firocoxib on Healthy Horses. Vet Sci, 10(9). https://doi.org/10.3390/vetsci10090531

Publication

Veterinary sciences
ISSN: 2306-7381
NlmUniqueID: 101680127
Country: Switzerland
Language: English
Volume: 10
Issue: 9

Researcher Affiliations

Araújo, Renatha A
  • Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.
Sales, Nathali A A
  • Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.
Basile, Roberta C
  • Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.
Feringer-Junior, Walter H
  • Department of Veterinary Medicine, Metropolitan University of Santos, UNIMES, Av. Gen. Francisco Glicério, 8, Santos 11045-002, SP, Brazil.
Apparício, Maricy
  • Department of Veterinary Surgery and Animal Reproduction, School of Veterinary Medicine and Animal Science, São Paulo State University (UNESP), Rua Professor Doutor Walter Mauricio Correa, s/n., Botucatu 18618-681, SP, Brazil.
Ferraz, Guilherme C
  • Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.
Queiroz-Neto, Antonio
  • Laboratory of Equine Exercise Physiology and Pharmacology (LAFEQ), Department of Animal Morphology and Physiology, School of Agricultural and Veterinary Studies, São Paulo State University, FCAV/UNESP, Via de Acesso Prof. Paulo D. Castellane s/n., Jaboticabal 14884-900, SP, Brazil.

Grant Funding

  • 10/10992-2 / São Paulo Research Foundation

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 62 references
  1. Fiorin EV, Rodrigues NNP, Cota LDO, Seidel SRT, Barbosa AP, Tokawa PKA. Clinical study of chondroitin sulfate urinary excretion following intramuscular application of the chondroitin sulfate and glucosamine association in horses.. Arq Bras Med Vet Zootec 2023;75:355–359.
    doi: 10.1590/1678-4162-12839google scholar: lookup
  2. Menzies-Gow N. Colic: Medical treatment and management in horses.. Vet. Times 2016;46:19–20.
  3. Lees P, Landoni MF, Giraudel J, Toutain PL. Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in veterinary species.. J. Vet. Pharmacol. Ther. 2004;27:479–490.
    doi: 10.1111/j.1365-2885.2004.00617.xpubmed: 15601442google scholar: lookup
  4. Krötz F, Schiele TM, Klauss V, Sohn H-Y. Selective COX-2 inhibitors and risk of myocardial infarction.. J. Vasc. Res. 2005;42:312–324.
    doi: 10.1159/000086459pubmed: 15976506google scholar: lookup
  5. Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of COX-2-selective inhibitors.. Am. J. Nephrol. 2001;21:1–15.
    doi: 10.1159/000046212pubmed: 11275626google scholar: lookup
  6. Clark TP. The clinical pharmacology of cyclooxygenase-2–selective and dual inhibitors.. Vet. Clin. N. Am. Small Anim. Pract. 2006;36:1061–1085.
    doi: 10.1016/j.cvsm.2006.07.001pubmed: 16984827google scholar: lookup
  7. Kvaternick V, Pollmeier M, Fischer J, Hanson P. Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses.. J. Vet. Pharmacol. Ther. 2007;30:208–217.
    doi: 10.1111/j.1365-2885.2007.00840.xpubmed: 17472652google scholar: lookup
  8. Simmons DL, Xie W, Chipman JG, Evett GE. Multiple Cyclooxygenases: Cloning of a Mitogen-Inducible Form.. 1991. In: Bailey JM, editor. Prostaglandins, Leukotrienes, Lipoxins, and PAF: Mechanism of Action, Molecular Biology, and Clinical Applications. Springer; Boston, MA, USA: pp. 67–78.
  9. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: Critical remarks.. Curr. Med. Chem. 2002;9:1033–1043.
    doi: 10.2174/0929867024606650pubmed: 12733982google scholar: lookup
  10. FitzGerald GA. Coxibs and Cardiovascular Disease.. N. Engl. J. Med. 2004;351:1709–1711.
    doi: 10.1056/NEJMp048288pubmed: 15470192google scholar: lookup
  11. Macpherson ML, Giguère S, Pozor MA, Burden CA, Berghaus LJ, Berghaus RD, Varner JC, Hayna JT, Benson SM, Randell SA. Evidence for anti-inflammatory effects of firocoxib administered to mares with experimentally induced placentitis.. Am. J. Reprod. Immunol. 2021;86:e13396.
    doi: 10.1111/aji.13396pubmed: 33569862google scholar: lookup
  12. McCann ME, Andersen DR, Zhang D, Brideau C, Black WC, Hanson PD, Hickey GJ. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.. Am. J. Vet. Res. 2004;65:503–512.
    doi: 10.2460/ajvr.2004.65.503pubmed: 15077695google scholar: lookup
  13. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.. Vet. Anim. Sci. 2023;19:100286.
    doi: 10.1016/j.vas.2023.100286pmc: PMC9852958pubmed: 36684818google scholar: lookup
  14. Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis.. J. Vet. Med. Res. 2014;5:159–168.
    pmc: PMC7337192pubmed: 32670856
  15. F.D.A. (Food and Drug Administration). NADA 141-250. Previcox Chewable Tablets—Firocoxib.. 2004. US Food and Drug Administration; Rockville, MD, USA: Freedom of Information Summary.
  16. F.D.A. (Food and Drug Administration). NADA 141-253. Equioxx Oral Paste-Firocoxib.. 2005. US Food and Drug Administration; Rockville, MD, USA: Freedom of Information Summary.
  17. Cook VL, Meyer CT, Campbell NB, Blikslager AT. Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum.. Am. J. Vet. Res. 2009;70:992–1000.
    doi: 10.2460/ajvr.70.8.992pubmed: 19645580google scholar: lookup
  18. Tomlinson JE, Wilder BO, Young KM, Blikslager AT. Effects of flunixin meglumine or etodolac treatment on mucosal recovery of equine jejunum after ischemia.. Am. J. Vet. Res. 2004;65:761–769.
    doi: 10.2460/ajvr.2004.65.761pubmed: 15198216google scholar: lookup
  19. Tomlinson J, Blikslager A. Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum.. Equine Vet. J. 2005;37:75–80.
    doi: 10.2746/0425164054406865pubmed: 15651739google scholar: lookup
  20. Little D, Jones SL, Blikslager AT. Cyclooxygenase (COX) inhibitors and the intestine.. J. Vet. Intern. Med. 2007;21:367–377.
    doi: 10.1111/j.1939-1676.2007.tb02978.xpubmed: 17552439google scholar: lookup
  21. Poonam D, Vinay CS, Gautam P. Cyclo-oxygenase-2 expression and prostaglandin E2 production in experimental chronic gastric ulcer healing.. J. Vet. Intern. Med. 2005;519:277–284.
    doi: 10.1016/j.ejphar.2005.06.055pubmed: 16139265google scholar: lookup
  22. Sánchez-Fidalgo S, Martín-Lacave I, Illanes M, Motilva V. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor.. Eur. J. Pharmacol. 2004;505:187–194.
    doi: 10.1016/j.ejphar.2004.10.019pubmed: 15556152google scholar: lookup
  23. MacAllister C, Andrews F, Deegan E, Ruoff W, Olovson SG. A scoring system for gastric ulcers in the horse.. Equine Vet. J. 1997;29:430–433.
    doi: 10.1111/j.2042-3306.1997.tb03154.xpubmed: 9413714google scholar: lookup
  24. Jericó MASF. Antiinflamatórios.. 2008. In: Andrade SF, editor. Manual de Terapêutica Veterinária. 3rd ed. Roca; São Paulo, Brazil: pp. 115–140.
  25. Gentry PBH, Wood D. Hemostasis.. 2008. In: Kaneko JJHJW, Bruss ML, editors. Clinical Biochemistry of Domestic Animals. 6th ed. Academic Press; San Diego, CA, USA: pp. 379–412.
  26. Murray MJ, Nout YS, Ward DL. Endoscopic findings of the gastric antrum and pylorus in horses: 162 cases (1996–2000). J. Vet. Intern. 2001;15:401–406.
    pubmed: 11467600
  27. Kaneko JJ. Carbohydrate Metabolism and its diseases.. 2008. In: Kaneko JJHJW, Bruss ML, editors. Clinical Biochemistry of Domestic Animals. 6th ed. Academic Press; San Diego, CA, USA: pp. 45–80.
  28. Sellon DC. Disorders of the Hematopoietic System.. 1998. In: Reed SM, Bayly WM, Sellon DC, editors. Equine Internal Medicine. 2nd ed. Saunders; Philadelphia, PA, USA: pp. 721–769.
  29. Navab F, Steingrub J. Stress ulcer: Is routine prophylaxis necessary?. Am. J. Gastroenterol. 1995;90:708–712.
    pubmed: 7733073
  30. Mozaffari AA, Derakhshanfar A, Alinejad A, Morovati M. A comparative study on the adverse effects of flunixin, ketoprofen and phenylbutazone in miniature donkeys: Haematological, biochemical and pathological findings.. N. Engl. Vet. J. 2010;58:224–228.
    doi: 10.1080/00480169.2010.69295pubmed: 20927172google scholar: lookup
  31. Lecoindre O, Pepin-Richard C. Tolerance of firocoxib in dogs with osteoarthritis during 90 days.. J. Vet. Pharmacol. Ther. 2011;34:190–192.
    doi: 10.1111/j.1365-2885.2010.01227.xpubmed: 21395612google scholar: lookup
  32. Barbosa CM, Sakate M, Camplesi AC, Vailati MdCF, Moraes LF, Takahira RK. Avaliações hematológicas e bioquímicas do uso de diclofenaco de sódio, meloxicam e firocoxibe em ratos.. Braz. J. Vet. Res. Anim. Sci. 2010;47:117–124.
    doi: 10.11606/issn.1678-4456.bjvras.2010.26835google scholar: lookup
  33. Zaterka S. Lesöes induzidas por AINEs no sitema digestório.. RBM Rev. Bras. Med. 2000;57:882.
  34. HealthMe [(accessed on 12 July 2023)]. Available online: https://www.ehealthme.com/ds/celecoxib/leukopenia/
  35. Marini-filho R. Alterações Hematológicas, Hemostáticas E Bioquímicas de Cães Tratados Com Anti-Inflamatórios Não Esteroidais.. 2011. Master’s Thesis. Universidade do Oeste Paulista; Presidente Prudente, Brazil.
  36. Araujo LF, Soeiro AdM, Fernandes JdL, Serrano Júnior CV. Eventos cardiovasculares: Um efeito de classe dos inibidores de COX-2.. Arq. Bras. Cardiol. 2005;85:222–229.
    doi: 10.1590/S0066-782X2005001600016pubmed: 16200274google scholar: lookup
  37. Hall JE. Guyton & Hall. Tratado de Fisiología Médica.. 2021. Elsevier Health Sciences; Amsterdam, The Netherlands.
  38. Meyer D, Coles EH, Rich LJ. Medicina de Laboratório Veterinária: Interpretação e Diagnóstico.. 2001. Roca; Barcelona, Spain.
  39. Pozzobon R. Avaliação Farmacocinética, Hematológica e Espermática de Pôneis Tratados Com Meloxicam.. 2010. Doctoral Thesis. Universidade Federal de Santa Maria; Santa Maria, Brazil.
  40. Bishop RC, McCoy AM, Kemper AM, Stewart RM, Wilkins PA. Short-term administration of flunixin meglumine or firocoxib does not alter viscoelastic coagulation profiles in healthy horses.. J. Am. Vet. Med. Assoc. 2022;260:1963–1966.
    doi: 10.2460/javma.22.08.0367pubmed: 36198050google scholar: lookup
  41. Curtis B, McFarland J, Wu G, Visentin G, Aster R. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex.. Blood 1994;84:176–183.
    doi: 10.1182/blood.V84.1.176.176pubmed: 7517207google scholar: lookup
  42. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: Pathogenesis, diagnosis, and management.. Thromb. J. 2009;7:911–918.
    doi: 10.1111/j.1538-7836.2009.03360.xpmc: PMC2935185pubmed: 19344362google scholar: lookup
  43. Lopes MAF, Dearo ACdO, Biondo AW, Godin LFP, Iamaguti P, Thomassian A, Kohayagawa A. Exame do fluido peritoneal e hemograma de eqüinos submetidos à laparotomia e infusão intraperitoneal de carboximetilcelulose.. Cienc. Rural. 1999;29:79–85.
    doi: 10.1590/S0103-84781999000100015google scholar: lookup
  44. Fraser CM. Manual Merck de Veterinária: Um Manual de Diagnóstico, Tratamento, Prevenção e Controle de Doenças Para o Veterinário.. 1991. 6th ed. Roca; São Paulo, Brazil: p. 1803.
  45. Trent AM. The peritoneum and peritoneal cavity.. 1995. In: Kobluk CNAT, Geor RJ, editors. The Horse Diseases & Clinical Management. Saunders; Philadelphia, PA, USA: pp. 373–404.
  46. Gobbi FP, Di Filippo PA, de Macêdo Mello L, Lemos GB, Martins CB, Albernaz AP, Quirino CR. Effects of flunixin meglumine, firocoxib, and meloxicam in equines after castration.. JEVS 2020;94:103229.
    doi: 10.1016/j.jevs.2020.103229pubmed: 33077071google scholar: lookup
  47. Schumacher J, Schumacher J, Spano J, McGuire J, Scrutchfield W, Feldman R. Effects of castration on peritoneal fluid in the horse.. J. Vet. Intern. Med. 1988;2:22–25.
    doi: 10.1111/j.1939-1676.1988.tb01973.xpubmed: 3221352google scholar: lookup
  48. Silva LAFD, França RO, Vieira D, Garcia AM, Moura MID, Silva MAMD, Batista ES, Trindade BR, Franco LG. Use of nylon clamp, catgut and emasculator to prevent hemostasy in ovariectomy in mares.. Ci. Anim. Bras. 2007;8:135–146.
  49. Weiss DJ, Wardrop KJ. Schalm’s Veterinary Hematology.. 2011. John Wiley & Sons; Hoboken, NJ, USA.
  50. Boelsterli UA. Mechanisms of NSAID-Induced Hepatotoxicity.. Drug Saf. 2002;25:633–648.
    doi: 10.2165/00002018-200225090-00003pubmed: 12137558google scholar: lookup
  51. Steagall P, Mantovani F, Ferreira T, Salcedo E, Moutinho F, Luna SPL. Evaluation of the adverse effects of oral firocoxib in healthy dogs.. J. Vet. Pharmacol. Ther. 2007;30:218–223.
    doi: 10.1111/j.1365-2885.2007.00842.xpmc: PMC7194286pubmed: 17472653google scholar: lookup
  52. Satué K, Miguel-Pastor L, Chicharro D, Gardón JC. Hepatic Enzyme Profile in Horses.. Animals 2022;12:861.
    doi: 10.3390/ani12070861pmc: PMC8996839pubmed: 35405850google scholar: lookup
  53. Teixeira-Neto AR, Ferraz GC, Moscardini ARC, Balsamão GM, Souza JCF, Queiroz-Neto A. Alterations in muscular enzymes of horses competing long-distance endurance rides under tropical climate.. Arq. Bras. Med. Vet. Zootec. 2008;60:143–149.
    doi: 10.1590/S0102-09352008000300004google scholar: lookup
  54. Steiness E, Rasmussen F, Svendsen O, Nielsen P. A Comparative Study of Serum Creatine Phosphokinase (CPK) Activity in Rabbits, Pigs and Humans after Intramuscular Injection of Local Damaging Drugs.. Acta Pharmacol. Toxicol. 1978;42:357–364.
    doi: 10.1111/j.1600-0773.1978.tb02217.xpubmed: 581031google scholar: lookup
  55. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis.. Ann. Intern. Med. 2001;134:254.
    doi: 10.7326/0003-4819-134-3-200102060-00028pubmed: 11177350google scholar: lookup
  56. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib.. Postgrad. Med. J. 2001;77:548–550.
    doi: 10.1136/pmj.77.910.548pmc: PMC1742098pubmed: 11470953google scholar: lookup
  57. Dittrich R. Exames laboratoriais de avaliação hepática nos equinos: Perfil bioquímico sanguíneo.. Rev. Bras. Med. Equina 2012;2:48–66.
  58. Koene M, Goupil X, Kampmann C, Hanson PD, Denton D, Pollmeier MG. Field Trial Validation of the Efficacy and Acceptability of Firocoxib, a Highly Selective Cox-2 Inhibitor, in a Group of 96 Lame Horses.. J. Equine Vet. Sci. 2010;30:237–243.
    doi: 10.1016/j.jevs.2010.03.011google scholar: lookup
  59. Kivett L, Taintor J, Wright J. Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.. J. Vet. Pharmacol. Ther. 2014;37:413–416.
    doi: 10.1111/jvp.12097pubmed: 24354928google scholar: lookup
  60. Adam MI, Köller G, Arnold C, Schusser GF. Effects of using Flunixin Meglumine, Metamizole, and Phenylbutazone on equine kidney functions, urinary mucus, and secretory Immunoglobulin A (IgA) concentrations.. Pferdeheilkunde 2017;33:263–270.
    doi: 10.21836/PEM20170307google scholar: lookup
  61. Doucet MY, Bertone AL, Hendrickson D, Hughes F, MacAllister C, McClure S, Reinemeyer C, Rossier Y, Sifferman R, Vrins AA. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J. Am. Vet. Med. Assoc. 2008;232:91–97.
    doi: 10.2460/javma.232.1.91pubmed: 18167116google scholar: lookup
  62. Divers TJ. COX Inhibitors: Making the Best Choice for the Laminitic Case.. J. Equine Vet. Sci. 2008;28:367–369.
    doi: 10.1016/j.jevs.2008.04.006google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.